RESUMEN
INTRODUCTION: Pneumonia is one of the most common indications for antibiotic. Shortening the duration of antibiotic therapy should help reduce bacterial resistance. To date, three randomized control trials have shown non-inferiority of short courses of antibiotic therapy (3 days) compared with 7 days in non-severe pneumonia. The aim of this study was to assess this strategy in real life. METHOD: This retrospective observational cohort study included all patients with pneumonia hospitalized in an internal medical ward from 11/01/2022 to 05/31/2023. We implemented the strategy based on early discontinuation of antibiotic therapy in patients with pneumonia who were clinically stable after 3 days of ß-lactam treatment. RESULTS: Among 49 patients included, median age was 72, median antibiotic duration was 4 days (IQR 3-6), and cure rate at D30 was 88 %. At day 30, we observed one death (2 %), four new antibiotic therapy (9 %), and two new hospitalisation (5 %), among five immunosuppressed patients. Among immunosuppressed patients (n=17; 35 %), failure rate was three times higher in case of short antibiotic courses (3/8; 38 %) than long antibiotic courses (1/7; 14 %). CONCLUSION: Strategy based on early discontinuation of antibiotic therapy in immunocompetent patients with pneumonia who were clinically stable after 3 days of ß-lactam treatment is safe, and easy to implement in a medical ward.
Asunto(s)
Antibacterianos , Hospitalización , Humanos , Antibacterianos/uso terapéutico , Antibacterianos/administración & dosificación , Femenino , Masculino , Anciano , Estudios Retrospectivos , Persona de Mediana Edad , Estudios de Cohortes , Hospitalización/estadística & datos numéricos , Anciano de 80 o más Años , Neumonía Bacteriana/tratamiento farmacológico , Neumonía Bacteriana/epidemiología , Esquema de Medicación , Factores de Tiempo , Neumonía/tratamiento farmacológico , Neumonía/epidemiología , Resultado del TratamientoRESUMEN
BACKGROUND: Prior studies have assessed the impact of the pretransplantation recipient body mass index (BMI) on patient outcomes after lung transplantation (LT), but they have not specifically addressed early postoperative complications. Moreover, the impact of donor BMI on these complications has not been evaluated. The first aim of this study was to assess complications during hospitalization in the ICU after LT according to donor and recipient pretransplantation BMI. METHODS: All the recipients who underwent LT at Bichat Claude Bernard Hospital, Paris, between January 2016 and August 2022 were included in this observational retrospective monocentric study. Postoperative complications were analyzed according to recipient and donor BMIs. Univariate and multivariate analyses were also performed. The 90-day and one-year survival rates were studied. P < 0.05 was considered to indicate statistical significance. The Paris-North Hospitals Institutional Review Board approved the study. RESULTS: A total of 304 recipients were analyzed. Being underweight was observed in 41 (13%) recipients, a normal weight in 130 (43%) recipients, and being overweight/obese in 133 (44%) recipients. ECMO support during surgery was significantly more common in the overweight/obese group (p = 0.021), as were respiratory complications (primary graft dysfunction (PGD) (p = 0.006), grade 3 PDG (p = 0.018), neuroblocking agent administration (p = 0.008), prone positioning (p = 0.007)), and KDIGO 3 acute kidney injury (p = 0.036). However, pretransplantation overweight/obese status was not an independent risk factor for 90-day mortality. An overweight or obese donor was associated with a decreased PaO2/FiO2 ratio before organ donation (p < 0.001), without affecting morbidity or mortality after LT. CONCLUSION: Pretransplantation overweight/obesity in recipients is strongly associated with respiratory and renal complications during hospitalization in the ICU after LT.
Asunto(s)
Trasplante de Pulmón , Sobrepeso , Humanos , Índice de Masa Corporal , Sobrepeso/complicaciones , Estudios Retrospectivos , Obesidad/complicaciones , Factores de Riesgo , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/etiología , Trasplante de Pulmón/efectos adversos , Supervivencia de Injerto , Resultado del TratamientoRESUMEN
Objectives: To determine the value of ultrasound (US)-guided synovial biopsy for the diagnosis of infectious arthritis that could not be detected by other modalities. Material and methods: This descriptive study was conducted among 37 patients with arthritis (3 with shoulder arthritis, 2 with elbow arthritis, 7 with wrist arthritis, 15 with hip arthritis, 4 with knee arthritis, and 5 with ankle arthritis) who underwent US-guided synovial biopsy at Hanoi Medical University Hospital for the diagnosis of infec-tious arthritis that could not be detected by infection laboratory tests, imaging, and/or joint fluid culture. The results of US-guided synovial biopsy were positive for infectious arthritis when those of pathologi-cal analyses, bacterial cultures, and/or polymerase chain reaction test for tuberculosis were positive. The final diagnosis established when the patients were discharged from the hospital was compared with the US-guided synovial biopsy results to calculate the sensitivity and specificity for the diagnosis of infectious arthritis. Results: The median age of the patients was 60 years (range: 22-79 years), and two thirds were women. Infectious arthritis was determined as the final diagnosis in 18 patients. There was no significant difference in the infection laboratory test results, synovial thickness, or magnetic resonance imaging features apart from soft tissue abscess between the infectious and non-infectious arthritis groups (P > 0.05). The US-guided synovial biopsy results were positive in 17 patients. Compared with the sensitivity and specificity of the final diagnosis, those of the US-guided synovial biopsy results for the diagnosis of infectious arthritis were 94.4% and 100%, respectively. The Numerical Rating Scale score was ≤3 in most patients. There were neither vascular nor neurologic complications among the patients. Conclusion: Imaging features and laboratory test results are non-specific for infectious arthritis. US-guided synovial biopsy is a well-tolerated, safe method that has a high value for the diagnosis of infectious arthritis. This modality should then be recommended for patients with unclassified arthritis.
Asunto(s)
Artritis Infecciosa , Membrana Sinovial , Humanos , Femenino , Adulto Joven , Adulto , Persona de Mediana Edad , Anciano , Masculino , Membrana Sinovial/diagnóstico por imagen , Membrana Sinovial/patología , Ultrasonografía/métodos , Artritis Infecciosa/diagnóstico por imagen , Artritis Infecciosa/patología , Biopsia Guiada por Imagen/métodos , Líquido Sinovial , Ultrasonografía IntervencionalRESUMEN
Vertebral Osteomyelitis (VO) is a rare disease, which has seen a gradual increase in its incidence over the past years. Here, we report a case, showing how difficult it can be to diagnose and manage a therapy in case of atypical microorganism. A 68-year-old man was hospitalized for a VO documented by blood cultures at Bacteroides fragilis. He first progressed favorably, but an increase in lumbar pain prompted, after an IRM, a percutaneous needle biopsy (PNB) that documented a recurrent VO at Corynebacterium striatum. In the face of this multi-microbial VO with atypicals microorganisms, a first PNB could have been discussed despite the positive blood cultures. This case report illustrates the complexity of management of VO, and its evolution according to the latest recommendations (interest of RMI during the follow-up, place of the TEP-scan, terms and conditions of immobilization, antibiotic administration methods).
Asunto(s)
Infecciones Bacterianas , Dolor de la Región Lumbar , Osteomielitis , Masculino , Humanos , Anciano , Antibacterianos/uso terapéutico , Infecciones Bacterianas/complicaciones , Dolor de la Región Lumbar/diagnóstico , Dolor de la Región Lumbar/etiología , Osteomielitis/diagnóstico , Osteomielitis/terapiaRESUMEN
These guidelines are an update of those made in 2007 at the request of the French Society of Infectious Diseases (SPILF, Société de Pathologie Infectieuse de Langue Française). They are intended for use by all healthcare professionals caring for patients with disco-vertebral infection (DVI) on spine, whether native or instrumented. They include evidence and opinion-based recommendations for the diagnosis and management of patients with DVI. ESR, PCT and scintigraphy, antibiotic therapy without microorganism identification (except for emergency situations), therapy longer than 6 weeks if the DVI is not complicated, contraindication for spinal osteosynthesis in a septic context, and prolonged dorsal decubitus are no longer to be done in DVI management. MRI study must include exploration of the entire spine with at least 2 orthogonal planes for the affected level(s). Several disco-vertebral samples must be performed if blood cultures are negative. Short, adapted treatment and directly oral antibiotherapy or early switch from intravenous to oral antibiotherapy are recommended. Consultation of a spine specialist should be requested to evaluate spinal stability. Early lifting of patients is recommended.
Asunto(s)
Antibacterianos , Columna Vertebral , Humanos , Adulto , Antibacterianos/uso terapéuticoAsunto(s)
Enfermedades Transmisibles , Telemedicina , Francia , Humanos , Atención Primaria de SaludRESUMEN
INTRODUCTION: Pneumomediastinum, which can be spontaneous or secondary, is defined by the presence of free air in the mediastinum as shown on a chest X-ray and/or chest CT, with or without subcutaneous emphysema. Secondary pneumomediastinum develops in various contexts (thoracic traumatism, perforation of central airway or digestive tract, pneumothorax, barotraumatism complicating mechanical ventilation ). Spontaneous pneumomediastinum , which will be the focus of this review, develops without any of the above-mentioned conditions. STATE OF ART: Spontaneous pneumomediastinum is a rare entity which usually occurs in young people either without medical history or with an history of asthma. A trigger event is detected in 40% to 60% of cases. Positive diagnosis is made on chest radiographt but thoracic CT is more sensitive. Distinction between spontaneous pneumomediastinum and secondary pneumomediastinum is in general easy but may sometimes be more difficult, particularly in case of oesophageal perforation. The evolution of spontaneous pneumomediastinum is most often benign but, rare complications may occur. Management is most often conservative. PERSPECTIVES: There is no consensual management of spontaneous pneumediastinum because of the lack of randomized prospective studies. This may be explained by the rarity of the disease. The actual trend is to offer to the patients a conservative treatment, which could be ambulatory in some cases. CONCLUSIONS: Spontaneous pneumomediastinum is a rare entity developing mainly in young subjects. The evolution is in general benign, justifying a conservative approach.
Asunto(s)
Enfisema Mediastínico , Neumotórax , Enfisema Subcutáneo , Adolescente , Humanos , Enfisema Mediastínico/complicaciones , Enfisema Mediastínico/diagnóstico , Mediastino , Neumotórax/diagnóstico , Neumotórax/etiología , Neumotórax/terapia , Estudios Prospectivos , Enfisema Subcutáneo/diagnóstico , Enfisema Subcutáneo/etiología , Enfisema Subcutáneo/terapiaRESUMEN
The coronavirus disease 2019 (COVID-19) outbreak has become a worldwide public health concern. Cardiovascular complications are relatively frequent, reaching 20% of COVID-19 patients and 43% of COVID-19 patients admitted in Intensive Care Unit. Cardiac injury mechanisms are multiple, including hyperinflammation, pro-coagulant and pro-thrombotic states, sepsis related cardiomyopathy, hypoxia in relation with lung severity, hemodynamic instability, cytokine storm, critically illness, direct myocardial insult by acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and stress cardiomyopathy. The authors report a narrative review about cardio-vascular complications and predictive factors of mortality in patients infected with COVID-19.
Asunto(s)
COVID-19/complicaciones , Enfermedades Cardiovasculares/etiología , COVID-19/mortalidad , Enfermedades Cardiovasculares/mortalidad , Humanos , PronósticoRESUMEN
Guidelines for the management of carbapenemase-producing Enterobacterales (CPE) infections recommend a combination of two active agents, including meropenem if the minimum inhibitory concentration (MIC) is ≤8 mg/L. The therapeutic equivalence of meropenem generics has been challenged. We compared the bactericidal activity of meropenem innovator (AstraZeneca) and four generic products (Actavis, Kabi, Mylan and Panpharma), both in vitro and in vivo, in association with colistin. In vitro time-kill studies were performed at 4 × MIC. An experimental model of KPC-producing Klebsiella pneumoniae osteomyelitis was induced in rabbits by tibial injection of a sclerosing agent followed by 2 × 108 CFU of K. pneumoniae KPC-99YC (meropenem MIC = 4 mg/L; colistin MIC = 1 mg/L). At 14 days after inoculation, treatment for 7 days started in seven groups of ≥10 rabbits, including a control group, a colistin group, and one group for each meropenem product (i.e. the innovator and four generics), in combination with colistin. In vitro, meropenem + colistin was bactericidal with no viable bacteria after 6 h, and this effect was similar with all meropenem products. In the osteomyelitis model, there was no significant difference between meropenem generics and the innovator when combined with colistin. Colistin-resistant strains were detected after treatment with colistin + meropenem innovator (n = 3) and generics (n = 3). The efficacy of four meropenem generics did not differ from the innovator in vitro and in an experimental rabbit model of KPC-producing K. pneumoniae osteomyelitis in terms of bactericidal activity and the emergence of resistance.
Asunto(s)
Enterobacteriaceae Resistentes a los Carbapenémicos/efectos de los fármacos , Colistina/uso terapéutico , Medicamentos Genéricos/uso terapéutico , Klebsiella pneumoniae/efectos de los fármacos , Meropenem/uso terapéutico , Osteomielitis/tratamiento farmacológico , Animales , Proteínas Bacterianas/metabolismo , Modelos Animales de Enfermedad , Farmacorresistencia Bacteriana Múltiple , Quimioterapia Combinada , Medicamentos Genéricos/farmacocinética , Infecciones por Klebsiella/tratamiento farmacológico , Meropenem/sangre , Meropenem/farmacocinética , Pruebas de Sensibilidad Microbiana , Osteomielitis/microbiología , Conejos , Equivalencia Terapéutica , beta-Lactamasas/metabolismoRESUMEN
OBJECTIVES: Limited data have been reported regarding osteomyelitis due to carbapenemase-producing Enterobacteriaceae (CPE), including co-infections with extended-spectrum ß-lactamase (ESBL)-producing micro-organisms. METHODS: We conducted a retrospective study in a reference centre for bone and joint infections from 2011 to 2019 among patients infected with CPE. RESULTS: Nine patients (mean age 46.8 ± 16.6 years), including three with infected implants, were identified. Infections were mostly polymicrobial (n = 8/9), including Staphylococcus aureus (n = 6/9). CPE were mainly OXA-48-type, associated with ESBL-producing Enterobacteriaceae (n = 8/9), of which 5/9 isolates were Klebsiella pneumoniae. Control of the infection was achieved in seven cases. CONCLUSIONS: CPE osteomyelitides are essentially polymicrobial and fluoroquinolone-resistant infections, highlighting the need for efficient surgery with implant removal.
Asunto(s)
Enterobacteriaceae Resistentes a los Carbapenémicos , Infecciones por Enterobacteriaceae , Osteomielitis , Adulto , Proteínas Bacterianas/genética , Humanos , Persona de Mediana Edad , Estudios Retrospectivos , beta-Lactamasas/genéticaRESUMEN
BACKGROUND: Acute kidney injury (AKI) is associated with increased short-term and long-term mortality and morbidity after lung transplantation (LT). The primary objective of this study was to analyze the perioperative factors associated with AKI according to Kidney Disease: Improving Global Outcome (KDIGO) criteria during hospitalization in an intensive care unit (ICU) after LT. METHODS: This was a single-center, observational, prospective study. AKI was defined according to KDIGO criteria. Results are expressed as median, interquartile range, absolute numbers, and percentages. Statistical analyses were performed using χ2 test, Fisher exact test, and Mann-Whitney U test. P < .05 was considered to be significant. Multivariate analysis was performed to identify independent risk factors. RESULTS: Between January 2016 and April 2018, 94 patients underwent LT (70% bilateral LT). AKI occurred during ICU stay in 46 patients (49%). KDIGO 1 AKI was observed in 16 patients (17%), KDIGO 2 in 14 patients (15%), and KDIGO 3 in 16 patients (17%), including 12 patients (75%) who required renal replacement therapy. AKI occurred before the fifth day after surgery for 38 patients (82% of the AKI patients). On multivariate analysis, independent factors associated with AKI were bilateral LT and mechanical ventilation >3 days (odds ratio [OR] 4.26, 95% confidence interval [CI] [1.49; 13.63] P = .010 and OR 5.56 [1.25; 11.47] P = .018, respectively). AKI and the need for renal replacement therapy were significantly associated with ICU mortality, 28-day mortality, and 1-year mortality. CONCLUSION: AKI is common during ICU stay after LT, especially after bilateral LT, and is associated with prolonged mechanical ventilation and increased short-term and long-term mortality.
Asunto(s)
Lesión Renal Aguda/etiología , Trasplante de Pulmón/efectos adversos , Lesión Renal Aguda/epidemiología , Adulto , Anciano , Femenino , Humanos , Incidencia , Trasplante de Pulmón/mortalidad , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Periodo Perioperatorio , Estudios Prospectivos , Terapia de Reemplazo Renal , Respiración Artificial , Factores de RiesgoAsunto(s)
Aorta Abdominal/cirugía , Prótesis Vascular/efectos adversos , Infecciones Relacionadas con Prótesis/etiología , Fiebre Q/etiología , Anciano , Humanos , Masculino , Infecciones Relacionadas con Prótesis/diagnóstico , Infecciones Relacionadas con Prótesis/terapia , Fiebre Q/diagnóstico , Fiebre Q/terapiaAsunto(s)
Fasciculación/inducido químicamente , Fluoroquinolonas/efectos adversos , Enfermedad de la Neurona Motora/inducido químicamente , Neuronas Motoras/efectos de los fármacos , Adulto , Fasciculación/fisiopatología , Fluoroquinolonas/administración & dosificación , Humanos , Masculino , Enfermedad de la Neurona Motora/fisiopatología , Neuronas Motoras/fisiología , Cuadriplejía/tratamiento farmacológico , Cuadriplejía/fisiopatologíaRESUMEN
BACKGROUND: Fungus-positive respiratory samples (FPRS) are common in the intensive Care unit (ICU) and are usually considered to correspond to colonization. The management of FPRS during the early postoperative course after lung transplantation (LT) remains unclear. The epidemiology, clinical consequences, and prognosis of FPRS were assessed in LT recipients. METHODS: Over a 6-year period, we analyzed the postoperative ICU course of 176 LT recipients with a specific focus on microbiological results of routine respiratory samples and clinical course. The outcomes during the ICU stay at day 28 and at 1 year were compared in patients with or without FPRS. Results are expressed as median and interquartile range. RESULTS: In the pretransplantation period, Candida spp were reported in 17% of patients. No routine post-LT antifungal prophylaxis was initiated. In the post-LT period, at least 1 FPRS was observed in 69% of patients (93% Candida spp, 7% Aspergillus spp). Double LT (odds ratio = 4.15, 95% confidence interval [1.67-11.80], P = .0007) was the only risk factor associated with Candida spp in respiratory samples. Antifungal therapy was administered in 58% of patients with post-LT Candida-positive samples. Candida spp in post-LT respiratory samples were not associated with increased ICU, 28-day, or 1-year mortality rates. CONCLUSION: A high prevalence of FPRS is reported after LT, mainly with Candida spp. The lack of association between post-LT FPRS and mortality and morbidity suggests avoiding antifungal therapy in the absence of clinical signs of invasive infection.
Asunto(s)
Trasplante de Pulmón , Micosis/epidemiología , Micosis/etiología , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/microbiología , Candida , Femenino , Humanos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Prevalencia , Pronóstico , Sistema Respiratorio/microbiología , Factores de RiesgoRESUMEN
We report the case of an 18-year-old immunocompetent man who presented to the hospital with fever, headaches, and arthromyalgia, which progressed to include an erythematous rash. He had a history of a tick bite 72 h earlier. The diagnosis of rickettsial infection was suspected and a course of doxycycline was initiated for a total of 5 days. His evolution was rapidly favorable under treatment, with resolution of the symptoms within 24 h. Blood cultures came back positive for Neisseria meningitidis serotype B, indicating an authentic purpura fulminans. Purpura fulminans is a medical emergency, a syndrome of intravascular thrombosis characterized by a very rapid evolution that requires early recognition and specific treatment. It is commonly described in the young and healthy patient and has high mortality and morbidity. Common bacteria mainly associated with purpura fulminans are Meningococcus spp., Pneumococcus spp., and Staphylococcus spp.
Asunto(s)
Antibacterianos/uso terapéutico , Bacteriemia/tratamiento farmacológico , Doxiciclina/uso terapéutico , Infecciones Meningocócicas/tratamiento farmacológico , Púrpura Fulminante/tratamiento farmacológico , Adolescente , Fiebre/microbiología , Humanos , Masculino , Neisseria meningitidis , Púrpura Fulminante/microbiología , Resultado del TratamientoAsunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/efectos adversos , Programas de Optimización del Uso de los Antimicrobianos/métodos , Programas de Optimización del Uso de los Antimicrobianos/normas , Esquema de Medicación , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/epidemiología , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/prevención & control , Hospitalización/estadística & datos numéricos , Humanos , Factores de TiempoRESUMEN
INTRODUCTION: Community acquired pneumonia (CAP) accounts for a large part of antibiotic prescriptions in France. The significant ecological impact of antibiotics supports the development of strategies to improve their use, especially the reduction of treatment duration during CAP. STATE OF THE ART: During CAP, a strategy of early antibiotic discontinuation, subject to a favorable initial clinical course, or of a significantly decreasing procalcitonin kinetic, is supported by several studies. The reduction of antibiotic treatment duration leads to a decrease of the emergence of resistant bacteria. It may also be associated with a better treatment observance and a decrease in costs and side effects. PERSPECTIVES: Diagnostic tests based on molecular biology, especially those including some bacterial targets in their panel, allow an increase on microbiological documentation rates during CAP. They should enable the elaboration of therapeutic strategies for a better use of the antibiotics. CONCLUSIONS: These strategies of antibiotic treatment rationalization during CAP may be associated with a high benefit-risk ratio both at the individual and the community scales. Particularly, they may allow a substantial ecologic gain in this era of resistant bacteria.